ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,303.27
0.12%
Dow Jones
40,003.59
0.34%
US Dollar vs MXN
16.6085
-0.43%
Brent Oil
83.76
0.67%
Bitcoin
66,887.11
2.53%
Registration Strip Icon for charts Regístrate para obtener gráficos en tiempo real, herramientas de análisis y precios.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. Syros Pharmaceuticals Inc (SYRS)

  7. Syros Pharmaceuticals Inc (SYRS) Noticias

SYRS

Syros Pharmaceuticals (SYRS)

Syros Pharmaceuticals Inc
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:NASDAQ:SYRS
FechaHoraFuenteTítuloSímboloCompañía
14/05/202406:30Business WireSyros Reports First Quarter 2024 Financial Results and Provides a Corporate UpdateNASDAQ:SYRSSyros Pharmaceuticals Inc
14/05/202405:42Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:SYRSSyros Pharmaceuticals Inc
07/05/202408:00Business WireSyros to Participate in Upcoming Investor ConferencesNASDAQ:SYRSSyros Pharmaceuticals Inc
07/05/202406:00Business WireSyros to Report First Quarter 2024 Financial Results on Tuesday, May 14, 2024NASDAQ:SYRSSyros Pharmaceuticals Inc
09/04/202406:00Business WireSyros Receives Fast Track Designation from the FDA for Tamibarotene for the Treatment of Newly Diagnosed Unfit AML with RARA gene overexpressionNASDAQ:SYRSSyros Pharmaceuticals Inc
02/04/202415:30Business WireSyros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:SYRSSyros Pharmaceuticals Inc
27/03/202406:30Business WireSyros Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Corporate UpdateNASDAQ:SYRSSyros Pharmaceuticals Inc
27/03/202405:57IH Market NewsU.S. Stock Index Futures Point to a Rebound, Oil See Declines in Early TradingNASDAQ:SYRSSyros Pharmaceuticals Inc
25/03/202406:00Business WireSyros Announces Completion of Enrollment of 190 Patients Necessary to Support Primary Endpoint Analysis in SELECT-MDS-1 Phase 3 TrialNASDAQ:SYRSSyros Pharmaceuticals Inc
20/03/202406:00Business WireSyros to Report Fourth Quarter and Full Year 2023 Financial Results on Wednesday, March 27, 2024NASDAQ:SYRSSyros Pharmaceuticals Inc
27/02/202406:00Business WireSyros to Participate in TD Cowen 44th Annual Health Care ConferenceNASDAQ:SYRSSyros Pharmaceuticals Inc
14/02/202419:56Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:SYRSSyros Pharmaceuticals Inc
13/02/202419:22Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:SYRSSyros Pharmaceuticals Inc
08/01/202406:06Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SYRSSyros Pharmaceuticals Inc
08/01/202406:00Business WireSyros Highlights Anticipated 2024 Milestones to Deliver on the Value of TamibaroteneNASDAQ:SYRSSyros Pharmaceuticals Inc
26/12/202316:19Edgar (US Regulatory)Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]NASDAQ:SYRSSyros Pharmaceuticals Inc
19/12/202315:53Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:SYRSSyros Pharmaceuticals Inc
19/12/202306:27Business WireSyros Announces Pricing of $45.0 million Underwritten Offering of Common Stock and Pre-Funded WarrantsNASDAQ:SYRSSyros Pharmaceuticals Inc
14/12/202315:24Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SYRSSyros Pharmaceuticals Inc
12/12/202315:12Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:SYRSSyros Pharmaceuticals Inc
06/12/202306:00Business WireSyros Announces Encouraging Initial Data from Randomized SELECT-AML-1 Phase 2 Clinical Trial Evaluating Tamibarotene in Combination with Venetoclax and AzacitidineNASDAQ:SYRSSyros Pharmaceuticals Inc
14/11/202306:30Business WireSyros Reports Third Quarter 2023 Financial Results and Provides a Corporate UpdateNASDAQ:SYRSSyros Pharmaceuticals Inc
07/11/202306:30Business WireSyros to Report Third Quarter 2023 Financial Results on Tuesday, November 14, 2023NASDAQ:SYRSSyros Pharmaceuticals Inc
20/10/202315:15Edgar (US Regulatory)Form SC 13D - General statement of acquisition of beneficial ownershipNASDAQ:SYRSSyros Pharmaceuticals Inc
02/10/202307:45Business WireSyros Announces Planned CEO Leadership Transition and Strategic Reorganization to Support Long-Term Business Growth and Maturation into a Commercial Biopharmaceutical CompanyNASDAQ:SYRSSyros Pharmaceuticals Inc
08/08/202306:30Business WireSyros Reports Second Quarter 2023 Financial Results and Provides a Corporate UpdateNASDAQ:SYRSSyros Pharmaceuticals Inc
01/08/202306:30Business WireSyros to Report Second Quarter 2023 Financial Results on Tuesday, August 8, 2023NASDAQ:SYRSSyros Pharmaceuticals Inc
08/06/202306:30Business WireSyros to Present at Sidoti June 2023 Virtual Small-Cap ConferenceNASDAQ:SYRSSyros Pharmaceuticals Inc
02/06/202315:28Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:SYRSSyros Pharmaceuticals Inc
02/06/202315:14Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:SYRSSyros Pharmaceuticals Inc
 Showing the most relevant articles for your search:NASDAQ:SYRS

Su Consulta Reciente

FX
EURMXN
Euro vs MXN
AMEX
SPY
SPDR S&P 500
NASDAQ
AAPL
Apple
COIN
ETHUSD
Ethereum
NYSE
XOM
Exxon Mobil
NYSE
MRK
Merck
NASDAQ
QQQ
Invesco QQQ Trust Series 1
USOTC
DTEGY
Deutsche Telekom (QX)
COIN
SOLUSD
Solana
NYSE
AXP
American Express
NASDAQ
GOOGL
Alphabet
NYSE
BAC
Bank of America
USOTC
RHHBY
Roche (QX)
NYSE
DIS
Walt Disney
FX
USDMXN
US Dollar vs MXN
NYSE
MCD
McDonalds
Delayed Upgrade Clock
ADVFN Logo

México
Empresa
Negocios
Popular
Obtener la aplicación

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados